Kristoffer Hellstrand | ISAL 2019 | Immunotherapy with histamine dihydrochloride and IL-2 in AML

ACUTE LEUKEMIAS XVII Biology and Treatment Strategies, February 24–27 2019, Munich, DE Kristoffer Hellstrand Sahlgrenska Cancer Center, Gothenburg, SE Interview Topic (English): Immunotherapy with histamine dihydrochloride and IL-2 in AML For more information and expert opinions in Acute Myeloid Leukemia (AML), please visit: www.amlglobalportal.com

Kristoffer Hellstrand | ISAL 2019 | Immunotherapy with histamine dihydrochloride and IL-2 in AML

Kristoffer Hellstrand | Preventing AML relapse with histamine dihydrochloride & low dose IL-2

Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML

Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival

Histamine dihydrochloride to prevent relapse in AML: development and ongoing research

Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC

The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)

Prof. Hellstrand about Ceplene at the IMNP Symposium, Acute Leukemias XVI (Munich, Feb 17)

Maintenance Therapy in AML

Oncologists discuss Proleukin (Interleukin-2) immunotherapy

Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich

Proleukin (aldesleukin) Immunotherapy Patient Journey

Dr. Miletello Treats Kidney Cancer with Lifesaving IL-2 Immunotherapy at Baton Rouge General (WAFB)

Histamine dihydrochloride - Wikipedia Article Audio

Musa Yilmaz | ASCO 2018 | Can relapse occur in AML patients after a long period of remission?

GC10918 AT7867 dihydrochloride 1431697-86-7

Daniel Pollyea | ASH 2018 | Venetoclax plus HMAs in patients with AML unfit for intensive therapy